Alnylam is living the biotech dream, with not one but three products approved so far. However, for the group to move into the big league it needs to get a result in the Apollo-B trial of Onpattro in the cardiomyopathy subtype of ATTR amyloidosis.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,